Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions

Renal Failure

Volumn 31, Issue 3, 2009, Pages 221-228

  Ucar, Edip ^a   Huzmeli, Can ^a   Guven, Oguz ^a   Savas, Nazan ^a   Gullu, Murat ^a   Asilyoruk, Sema ^a   Kuvandik, Ceren ^b   Temizkan, Aysegul ^c   Kuvandik, Guven ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Kirikhan Government Hospital   (Turkey)

^c Kahramanmaras Pazarcik Government Hospital   (Turkey)

Author keywords

Cardiovascular disease; Hemodialysis; IDF; Metabolic syndrome; NCEP ATP III

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; FALSE POSITIVE RESULT; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL EXAMINATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; AGE; BLOOD; CARDIOVASCULAR DISEASE; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RENAL REPLACEMENT THERAPY; RISK FACTOR; ROC CURVE; TURKEY (REPUBLIC); WAIST CIRCUMFERENCE;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; ROC CURVE; TRIGLYCERIDES; TURKEY; WAIST CIRCUMFERENCE;

EID: 65549088995     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802669883     Document Type: Article

References (27)

1. Hansen BC. The metabolic syndrome X. Ann NY Acad Sci. 1999;892:1-24.
2. Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
3. Shoji T, Nishizawa Y. Chronic kidney disease as a metabolic syndrome with malnutrition - need for strict control of risk factors. Internal Medicine. 2005;44:179-187.
4. Bonora E, Kiechl S, Willeit J, et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord. 2003;27(10):1283-1289.
5. Zimmet P, Boyko EJ, Collier GR, De Courten M. Etiology of the metabolic syndrome: Potential role of insulin resistance, leptin resistance, and other players. Ann NY Acad Sci. 1999;892:25-44.
6. Nieuwdorp M, Stroes ES, Meijers JC, Büller H. Hypercoagu-lability in the metabolic syndrom. Current Opin Pharmacol. 2005;5:155-159.
7. World Health Organization Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva, Switzerland: WHO; 1999.
8. Camastra S, Bonora E, Del Prato S, Rett K, Weck M, Ferrannini E, for EGIR (European Group for the Study of Insulin Resistance). Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. Int J Obes Relat Metab Disord. 1999;23:1307-1313.
9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
10. Alberti K, Zimmet P, Shaw J. The IDF consensus worldwide definition of the metabolic syndrome. Lancet, 2005. International Diabetes Federation. Available at: http://www.idf.org
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:S5-S10.
13. Alberti KG, Zimmet PZ. Definition, diagnosis, and classification of diabetes mellitus and its complications, Part 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
14. Ford ES, et al. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26:575-581.
15. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: The role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996; 334:374-381.
16. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclin-ical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
17. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-966.
18. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 1999;22(Suppl. 3): C10-C13.
19. Wilson PW, D'Agostino RB, Levy D, Be-langer AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97: 1837-1847.
20. Stern MP, Williams K, Gonzalez-Villal-Pando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27:2676-2681 [erratum in Diabetes Care 2005;28:238].
21. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care. 2005;28:385-390.
22. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and on all causes in United States adults. Circulation. 2004;110:1245-1250.
23. Stern MP, Williams K, Hunt KJ. Impact on diabetes/ metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl. 2005;6:3-6.
24. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-1257.
25. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
26. Duncan GE, Perri MG, Theriaque DW, Hutson AD, Eckel RH, Stacpoole PW. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care. 2003;26:557-562.
27. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.